Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG reports news on a late-stage ophthalmology and neuro-ophthalmology pipeline focused on eye and optic-nerve disorders with unmet medical need. Company updates commonly cover OCS-01 eye drops for diabetic macular edema, Privosegtor for optic neuritis and other optic neuropathies, and Licaminlimab, a topical anti-TNFα candidate being developed for dry eye disease with a genotype-based approach.
Recurring developments include clinical-program updates, FDA and EMA regulatory interactions, scientific meeting presentations, pipeline reviews, financial results, capital-market communications, annual general meeting materials, and notifications of managerial transactions. Oculis is a Swiss biopharmaceutical company with ordinary shares traded on Nasdaq and Nasdaq Iceland under OCS.
Oculis Holding AG (Nasdaq: OCS) will hold a virtual conference call on April 13, 2023, from 8:00 am to 9:00 am ET to discuss its late-stage pipeline and clinical milestones. The company focuses on addressing significant medical needs in eye care, particularly in diabetic macular edema and dry eye disease. Oculis expects Stage 1 results from its Phase 3 DIAMOND study of OCS-01 later this year and plans to initiate two Phase 2 studies of OCS-02. Leading retina and anterior segment experts will participate in a Q&A session. A live audio webcast will be available on the company's website, with replay access for 30 days post-event.
Summary not available.
Oculis Holding AG (NASDAQ: OCS) has completed enrollment in its Phase 3 OPTIMIZE trial for OCS-01, a novel topical corticosteroid aimed at treating inflammation and pain post-ocular surgery. The trial involves 240 patients at 25 locations in the U.S., focusing on reducing inflammation by Day 15 and pain by Day 4. If approved, OCS-01 could be the first once-daily, preservative-free corticosteroid for this purpose. Additional results from the Phase 3 DIAMOND trial for diabetic macular edema (DME) are also anticipated later this year, hinting at further advancements in ocular treatments.